ARA A VAPORCIYAN to Disease Progression
This is a "connection" page, showing publications ARA A VAPORCIYAN has written about Disease Progression.
Connection Strength
0.160
-
Progression after chemotherapy is a novel predictor of poor outcomes after pulmonary metastasectomy in sarcoma patients. J Am Coll Surg. 2011 May; 212(5):821-6.
Score: 0.042
-
The potential role of aprotinin in the perioperative management of malignant tumors. J Am Coll Surg. 2004 Feb; 198(2):266-78.
Score: 0.025
-
Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer. Nat Commun. 2021 08 19; 12(1):5045.
Score: 0.021
-
Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas. Nat Commun. 2021 01 29; 12(1):687.
Score: 0.021
-
Importance of resection for locoregional disease control in Masaoka stage IVA thymic neoplasms. J Surg Oncol. 2020 Sep; 122(3):515-522.
Score: 0.020
-
Natural History of Ground-Glass Lesions Among Patients With Previous Lung Cancer. Ann Thorac Surg. 2018 06; 105(6):1671-1677.
Score: 0.017
-
Gender-based analysis of esophageal cancer patients undergoing preoperative chemoradiation: differences in presentation and therapy outcome. Dis Esophagus. 2006; 19(3):152-7.
Score: 0.007
-
Comparison of clinical stage, therapy response, and patient outcome between squamous cell carcinoma and adenocarcinoma of the esophagus. Int J Gastrointest Cancer. 2005; 36(2):69-76.
Score: 0.007